摘要
目的探讨芪蓝糖脂宁胶囊改善实验性糖尿病合并高脂血症大鼠血液高凝状态的作用机理。方法采用高糖高脂饲料喂饲2个月,小剂量(30mg·kg-1)一次性腹腔注射2%链脲佐菌素(STZ)的方法复制糖尿病合并高脂血症大鼠模型,造模成功后,灌胃给药,连续30d,测定各组大鼠血糖,血清脂质和血浆血栓素B2(TXB2)、6酮前列腺素F1α(6KetoPGF1α)的含量。结果芪蓝糖脂宁胶囊能明显降低实验大鼠血糖及血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDLC)的含量,升高高密度脂蛋白胆固醇(HDLC)的含量,降低血浆TXB2含量,升高6KetoPGF1α含量,使TXB26KetoPGF1α比值下降。结论芪蓝糖脂宁胶囊可通过调整TXB2与6KetoPGF1α平衡失调,改善血液高凝状态,从而为该药防治糖尿病血管病变提供实验依据。
Objective:To study the mechanism of Qilan Tangzhi Ning capsule improving the blood stagnation in rats with diabetes mellitus and hyperlipemia.Methods:Rats were fed with high sugar and fat food for 2 months,then 2% streptozocin(STZ,30mg·kg^-1 ) was injected intraperitoneally to induce hyperglycemia and hyperlipemia.After the model rats were administrated drugs for 30 days,the blood glucose,the serum lipids,the plasma TXB_2 and 6-Keto-PGF_~1α were detected.Results:Qilan Tangzhi Ning capsule could decrease the FBG and the serum TC,TG,LDL-C,increase HDL-C,decrease the TXB_2,increase the 6-Keto-PGF_~1α and decrease TXB_2/6-keto-PGF_~1α .Conclusion:Qilan Tangzhi Ning Capsule can adjust the balance of TXB_2 and 6-Keto-PGF_~1α to improve the blood stagnation,and prevent pathological changes of blood vessels in diabetes mellitus accordingly.
出处
《中国实验方剂学杂志》
CAS
2005年第2期43-45,共3页
Chinese Journal of Experimental Traditional Medical Formulae
